AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11251629
Drug: SR 48968C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 48968C (100 mg orally once daily for 9 days)
Trial: 30777117
Drug: Xuebijing (XBJ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuebijing (XBJ) injection
Trial: 30777117
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl injection (placebo control)
Trial: 25607558
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine emulsion (CsAE)
Trial: 16941406
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Aspirin (ASA) once daily
Trial: 16941406
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg Clopidogrel once daily
Trial: 15385014
Drug: S(+)‐ketamine 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine 1 mg x kg(‐1) (group K)
Trial: 15385014
Drug: S(+)‐ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine 0.5 mg x kg(‐1) plus clonidine 1 microg x kg(‐1) (group KC)
Trial: 11222185
Drug: 1.5 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL/kg of low osmolality contrast medium
Trial: 11222185
Drug: 150 mL
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mL of low osmolality contrast medium
Trial: 11222185
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of low osmolality contrast medium
Trial: 9444494
Drug: Trimipramine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimipramine and adjunct bright-light therapy
Trial: 7506176
Drug: nimesulide (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nimesulide (50mg granules twice daily)
Trial: 7506176
Drug: lysine-aspirin (360mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lysine-aspirin (360mg granules twice daily)
Trial: 29418016
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment (0.67 mg/m2/day)
Trial: 28678647
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide 5% gel
Trial: 24114421
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light therapy (IPL)
Trial: 15823625
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor moexipril added to combination therapy
Trial: 2045727
Drug: Methylphenidate (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (three levels of dosage)
Trial: 6768443
Drug: Thiotepa weekly
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Thiotepa weekly for one year (N = 90)
Trial: 6768443
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further therapy (Control group, N = 77)
Trial: 6768443
Drug: Thiotepa treatment
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Thiotepa treatment in negative node patients less than 55 years old
Trial: 25521726
Drug: Teprenone 150
RxNorm normalized name: teprenone
DrugBank: Teprenone (DB15955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teprenone 150 mg/day
Trial: 17889680
Drug: Slow injection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow injection (2.0 mL lidocaine with 1:80,000 epinephrine over 60 seconds)
Trial: 17889680
Drug: Rapid injection
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid injection (2.0 mL lidocaine with 1:80,000 epinephrine over 15 seconds)
Trial: 9205762
Drug: Ebrotidine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebrotidine 400 mg daily
Trial: 9205762
Drug: Ebrotidine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebrotidine 600 mg daily
Trial: 9205762
Drug: Ebrotidine 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebrotidine 800 mg daily
Trial: 9205762
Drug: Ebrotidine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebrotidine 200 mg daily
Trial: 7963150
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray (2 sprays per nostril once daily)
Trial: 3598772
Drug: 64 kcal/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 64 kcal/kg/d nonprotein energy plus 1 to 2 g/kg/d crystalline amino acids (Group 3)
Trial: 26764260
Drug: Disease activity-guided
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease activity-guided dose optimisation strategy of adalimumab or etanercept (TNFi)
Trial: 22542362
Drug: Eculizumab therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab therapy
Trial: 18317625
Drug: Low-calorie diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calorie diet plus orlistat 120 mg three times daily
Trial: 14722733
Drug: Tamoxifen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (40 mg/day)
Trial: 10333912
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus repaglinide
Trial: 10333912
Drug: Repaglinide (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (combined therapy)
Trial: 10333912
Drug: Repaglinide (monotherapy)
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide (monotherapy)
Trial: 10333912
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (metformin and repaglinide)
Trial: 7793116
Drug: Continuous s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous s.c. infusion of AVP (7.5 micrograms/d) for one week
Trial: 7793116
Drug: 0.9% NaCl-solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl-solution (placebo)
Trial: 2025476
Drug: Propofol 6
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 6 mg kg‐1 h‐1 after 90 min of nitrous oxide 66% in oxygen
Trial: 7344590
Drug: Acebutolol 400mg
RxNorm normalized name: acebutolol 400 MG
DrugBank: Acebutolol (DB01193)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acebutolol 400mg or more daily (once daily dosing)
Trial: 7344590
Drug: Acebutolol 400mg
RxNorm normalized name: acebutolol 400 MG
DrugBank: Acebutolol (DB01193)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acebutolol 400mg or more daily (twice daily dosing)
Trial: 28241159
Drug: Bright Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright Light Therapy (LT)
Trial: 28241159
Drug: Dim-Red Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim-Red Light Therapy (Control)
Trial: 19350472
Drug: Experimental add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental add-on therapy with D-Cycloserine
Trial: 14985175
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine intake (300-350 ml, approximately two glasses)
Trial: 14985175
Drug: White wine
RxNorm normalized name: White wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White wine intake (300-350 ml, approximately two glasses)
Trial: 3898645
Drug: Psychological biobehavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological biobehavioral treatment program
Trial: 30350844
Drug: Policosanol +
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol + aspirin
Trial: 22608359
Drug: CoQ10 60
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 60 mg twice daily
Trial: 15319673
Drug: Enfuvirtide (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enfuvirtide (90 mg twice daily) + optimized background regimen
Trial: 11921421
Drug: losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 50 mg daily
Trial: 1362671
Drug: Pen injector
RxNorm normalized name: Pen Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pen injector (Human NPH insulin in penfills)
Trial: 1362671
Drug: Syringe (Human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syringe (Human NPH insulin in vials)
Trial: 3516754
Drug: Hydrocortisone 17-butyrate
RxNorm normalized name: Cortisol 17-butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream
Trial: 3516754
Drug: Desonide (Apolar)
RxNorm normalized name: Desonide
DrugBank: Desonide sodium phosphate (DB15835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desonide (Apolar) 0.1% ointment
Trial: 30865051
Drug: Daily dosing
RxNorm normalized name: Osmolex 322 MG Daily Dosing Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing arm of FTC/TDF-based PrEP
Trial: 26510664
Drug: Clostridium butyricum
RxNorm normalized name: Clostridium butyricum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clostridium butyricum MIYAIRI (CBM) - 9 tablets orally once daily
Trial: 26510664
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 9 tablets orally once daily
Trial: 11472321
Drug: Ecabet sodium
RxNorm normalized name: ecabet sodium
DrugBank: Ecabet (DB05265)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecabet sodium 1 g b.d., amoxicillin 500 mg t.d.s. and clarithromycin 400 mg b.d. (EAC)
Trial: 11472321
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg (o.m.) with the same antimicrobial agents (LAC)
Trial: 7842354
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (1,000 mg/day for 2 weeks)
Trial: 7842354
Drug: Inert inositol
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert inositol tablets (control)
Trial: 2896383
Drug: Trimoprostil (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimoprostil (3 mg daily for 4 weeks)
Trial: 12381251
Drug: Pantoprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (20 mg once daily)
Trial: 10480346
Drug: Humanized antibody
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Humanized antibody against HER2 (Herceptin)
Trial: 10480346
Drug: Humanized antibody
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Humanized antibody against HER2 (Herceptin) combined with chemotherapy
Trial: 8548972
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% lignocaine ointment
Trial: 28718049
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin using a handheld, battery-operated, breath-actuated inhaler with aerosol generators producing 3-6 μm particle size distribution.
Trial: 28718049
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin with inspiratory flow of 10 L/min guided by LED.
Trial: 25497721
Drug: Low fibrinogen
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fibrinogen group (fibrinogen levels < 2 g/L or decreased by 25% or more)
Trial: 21379417
Drug: Artemether plus
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artemether plus lumefantrine (A+L)
Trial: 21379417
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with chloroquine plus sulfadoxine plus pyrimethamine (CQ+S+P)
Trial: 19910721
Drug: Atomoxetine (ATM)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ATM) 40-100 mg per day, n = 14
Trial: 17908591
Drug: CAT-152 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAT-152 (100 microg in 100 microl phosphate buffer) administered via 4 subconjunctival injections before and after trabeculectomy and at 1 week post-surgery.
Trial: 17908591
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via 4 injections before and after trabeculectomy and at 1 week post-surgery.
Trial: 14961887
Drug: Duloxetine 40
RxNorm normalized name: duloxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 40 mg BD for 12 weeks
Trial: 9241341
Drug: 2-Chloroprocaine (2-CP)
RxNorm normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-Chloroprocaine (2-CP) + epinephrine (Epi, 5 micrograms.ml-1)
Trial: 8363422
Drug: APSAC (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APSAC (30 mg i.v. over 5 minutes)
Trial: 8363422
Drug: rt-PA (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt-PA (10 mg bolus + 5000 IU of heparin as a bolus, followed by 90 mg rt-PA over 3 hours)
Trial: 3097293
Drug: L-carnitine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (50 mumol/kg/day)
Trial: 31378383
Drug: Combination (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (1 g paracetamol, 400 mg ibuprofen, 60 mg codeine)
Trial: 28331155
Drug: Celecoxib monotherapy
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib monotherapy (NSAID group)
Trial: 21598207
Drug: Occupational group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational group therapy, performed regularly 6 days a week
Trial: 9184950
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (standard protocol by continuous infusion)
Trial: 3297376
Drug: Alizapride (AZP)
DrugBank: Alizapride (DB01425)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alizapride (AZP) 2 mg/kg for 4 doses
Trial: 3297376
Drug: Alizapride (AZP)
DrugBank: Alizapride (DB01425)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alizapride (AZP) 2 mg/kg for 4 doses + Dexamethasone (DXM) 8 mg for five doses
Trial: 3297376
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MCP) 1 mg/kg for four doses + Dexamethasone (DXM) 8 mg for five doses
Trial: 25422488
Drug: Doxorubicin-cyclophosphamide administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin-cyclophosphamide administered continuously
Trial: 25422488
Drug: Paclitaxel administered
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel administered once per week
Trial: 25422488
Drug: Doxorubicin-cyclophosphamide administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin-cyclophosphamide administered once every 2 weeks
Trial: 25422488
Drug: Paclitaxel administered
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel administered once every 2 weeks
Trial: 21515996
Drug: Integrated care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated care service (n=36) including physical therapy, acupuncture, western medicines or herbal medicines
Trial: 21515996
Drug: Western care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western care (n=49) including physical therapy or western medicines
Trial: 19630713
Drug: Pharmacological aids
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological aids (e.g., nicotine replacement therapy, bupropion)
Trial: 16963397
Drug: Long-term follow-up
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term follow-up after completion of therapy
Trial: 9589359
Drug: Retinamide II
RxNorm normalized name: retinamide
DrugBank: Retinamidic acid (DB17418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinamide II (RII) suppositories, 10 mg QD, given intravaginally for 6 months (each course lasting 3 months)
Trial: 9589359
Drug: Retinamide II
RxNorm normalized name: retinamide
DrugBank: Retinamidic acid (DB17418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinamide II (RII) suppository intravaginally, once daily for 50 days in two courses
Trial: 9589359
Drug: Placebo, once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily for 50 days in two courses
Trial: 30880777
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1000 mg/day) for 4 weeks
Trial: 19375954
Drug: Full preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full preparation (2-L polyethylene glycol solution with 20 mL of sodium diatrizoate)
Trial: 19375954
Drug: Minimum preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimum preparation (45 mL of sodium diatrizoate and 10 mL of sodium picosulfate solution)
Trial: 19375954
Drug: Full preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full preparation
Trial: 19375954
Drug: Minimum preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimum preparation
Trial: 10682564
Drug: Fraxiparine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fraxiparine (0.4 ml hypodermically injected per day for 7 days)
Trial: 8583438
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium phosphate (Fleet PhosphoSoda)
Trial: 8583438
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol electrolyte (PEG) solution (GoLYTELY)
Trial: 632455
Drug: .3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: .3 mg/kg of Ritalin
Trial: 31462288
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy regimens (specific regimens not detailed)
Trial: 31462288
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy for patients with weight loss ≥10% at baseline
Trial: 28075381
Drug: n-3 PUFAs
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFAs (480 mg DHA and 720 mg EPA per day)
Trial: 23623474
Drug: Etonogestrel-releasing implant
RxNorm normalized name: etonogestrel Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etonogestrel-releasing implant
Trial: 20430565
Drug: Counseling programs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling programs with advice about nicotine replacement therapy (and additional bupropion‐SR in one of the programs)
Trial: 19644802
Drug: Etofibrate 1000
RxNorm normalized name: etofibrate
DrugBank: Etofibrate (DB08983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etofibrate 1000 mg/day for up to 12 months
Trial: 3383611
Drug: Controlled-release naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release naproxen (750 mg)
Trial: 3383611
Drug: Standard naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard naproxen (750 mg)
Trial: 28243834
Drug: Sodium Tanshinone
RxNorm normalized name: Tanshinone I
DrugBank: Tanshinone I (DB16886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Tanshinone IIA Sulfonate (STS) 60 mg/day
Trial: 25756440
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (fracture fixation or humeral head replacement)
Trial: 25756440
Drug: Nonsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical treatment (sling immobilization)
Trial: 24690891
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 4 ml/kg
Trial: 21597111
Drug: High concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration oxygen (8 l/min via medium concentration mask)
Trial: 16580376
Drug: Ovarian stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian stimulation with rhLH (150 IU daily) and rhFSH
Trial: 10690979
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 100 mg suppositories for 21 days
Trial: 10690979
Drug: Placebo suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppositories for 21 days
Trial: 9176035
Drug: L-lysine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-lysine infusion